EP0633943A1 - Therapie genique utilisant des vecteurs viraux cibles - Google Patents

Therapie genique utilisant des vecteurs viraux cibles

Info

Publication number
EP0633943A1
EP0633943A1 EP93908659A EP93908659A EP0633943A1 EP 0633943 A1 EP0633943 A1 EP 0633943A1 EP 93908659 A EP93908659 A EP 93908659A EP 93908659 A EP93908659 A EP 93908659A EP 0633943 A1 EP0633943 A1 EP 0633943A1
Authority
EP
European Patent Office
Prior art keywords
virus
envelope
protein
hybrid
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93908659A
Other languages
German (de)
English (en)
Other versions
EP0633943A4 (fr
Inventor
Alexander T. YOUNG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0633943A1 publication Critical patent/EP0633943A1/fr
Publication of EP0633943A4 publication Critical patent/EP0633943A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/854—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
    • C12N2810/856—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants from integrins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Definitions

  • Gene therapy is an approach to treating a broad range of diseases by delivering therapeutic genes directly into the human body.
  • Diseases that can potentially be cured by gene therapy include 1) diseases associated with the aging population such as cancer, heart disease, Alzheimer's disease, high blood pressure, atherosclerosis and arthritis; 2) viral infectious diseases such as acquired immune deficiency syndrome (AIDS) and herpes; and 3) inherited diseases such as diabetes, hemophilia, cystic fibrosis, and muscular dystrophy.
  • diseases associated with the aging population such as cancer, heart disease, Alzheimer's disease, high blood pressure, atherosclerosis and arthritis
  • viral infectious diseases such as acquired immune deficiency syndrome (AIDS) and herpes
  • AIDS acquired immune deficiency syndrome
  • herpes and 3) inherited diseases such as diabetes, hemophilia, cystic fibrosis, and muscular dystrophy.
  • a favored approach for human gene therapy involves the transplantation of genetically-altered cells into patients (Rosenberg, et al., 1988, New Eng J Medicine 311:570-578).
  • This approach requires the surgical removal of cells from each patient to isolate target cells from nontarget cells. Genes are introduced into these cells via viral vectors or other means, followed by transplantation of the genetically-altered cells back into the patient.
  • transplantation strategies are less likely to be suitable for treating diseases such as cystic fibrosis or cancer, where the diseased cells themselves must be corrected.
  • Double balloon catheterization transduces genes into cells within a defined arterial wall segment.
  • a double balloon catheter is inserted into an artery until the end of the catheter is located within the target area.
  • Inflation of two balloons at the end of the catheter creates an enclosed space into which retrovirus or DNA-loaded liposomes are infused.
  • This method has been successful in the transient expression of ⁇ -galactosidase genes within a defined segment of the ileofemoral artery of pigs (Nabel E.G., et al., 1990, Science 249:1285-1288) .
  • biolistic transfer and double balloon catheterization although locally specific, may be nonspecific in the individual cells that they transduce within the target area, creating a problem of inappropriate gene regulation if the transgene is expressed in nontarget cells.
  • biolistic transfer nor double balloon catheterization have been shown to be effective for the treatment of tissue occupying large volumes such as lungs, muscles, tumors, or cells of the systemic circulation since the majority of the cells would be inaccessible for in situ gene transfer.
  • a third approach to gene therapy is the delivery of genes to cells in vivo.
  • This approach involves the introduction of viral vectors directly into patients by injection, spray or other means.
  • Different species of viruses are engineered to deliver genes to the cells that the viruses normally infect.
  • Adenovirus for example, which normally infects lung cells, has been developed as a vector to target genes to lung cells (Rosenfield, et al., 1992, Cell .68.143-155).
  • Most viral vectors are single purpose vectors since they can only deliver genes to certain cells. Because the target cell specificity of viral vectors is restricted to the normal tropisms of the viruses, viral vectors are generally limited in that they either infect too broad a range of cell types, or they db not infect certain types of cells at all.
  • Liposomes have been designed to deliver genes or drugs to specific target cells in vivo. By chemically conjugating antibodies or ligands to liposomes, liposomes have been targeted to specific cells.
  • antisense env RNA has been delivered to human immunodeficiency virus (HIV)-infected lymphocytes using anti-CD3-conjugated liposomes (Renneisen, K., et al. , 1990, J Biol Chem 265:16337-16342): chloramphenicol transacetylase (CAT) genes have been delivered to H2K k positive lymphomas in H2K k -negative nude mice using anti- H2 k -conjugated liposomes (Wang, C.
  • HV human immunodeficiency virus
  • CAT chloramphenicol transacetylase
  • XGPRT xanthine guanine phosphoribosyltransferase
  • Wu et al. report a method to target naked DNA to specific cells. Asialoglycoprotein-DNA complexes are targeted to hepatocytes expressing the asialoglycoprotein receptor (Wu G.Y., et al., 1991, Biotherapy 3.:87-95). Similar to the problem encountered with immunotoxins, however, this strategy generally limits delivery of DNA to cells expressing receptors that are capable of DNA- internalization.
  • Antisense DNA technology is a method for inhibiting the expression of specific genes with complementary DNA (Moffat, 1991, Science 253:510-511) .
  • antisense DNA is specific in the genes that it affects, it is nonspecific in the types of cells that it gets into. This can create problems in vivo because it is desirable that endogenous genes in normal cells remain unaffected by antisense DNA (e.g., protooncogenes) .
  • the cost of manufacturing and administering antisense DNA may be high because the phosphate moieties of antisense DNA must be chemically modified to allow passage through the plasma membrane, a process which entails expensive organic chemistry.
  • Millimolar concentrations of antisense DNA are required to be effective, posing problems of potential toxicity in vivo.
  • Human gene therapy is therefore limited by-the available technology for gene delivery.
  • Transplantation strategies which require surgery, limit gene therapy to an expensive service industry for a small number of diseases.
  • Targeting of genes in situ through local transduction is generally not precise enough.
  • Viral vectors limit the delivery of genes in vivo to cells that the viruses normally infect. Liposome technologies may be infeasible because of the expense of production. Simple ligand-DNA complexes will not introduce genes into cells unless the receptors, against which the ligands are directed, internalize. Accordingly, currently available gene delivery systems impose severe limitations on the spectrum of diseases that can be treated by gene therapy. Summary of the Invention
  • the invention features a method for expressing a nucleic acid of interest in a heterologous host cell.
  • the method involves providing a virus whose genome comprises i) the nucleic acid of interest, and ii) a hybrid envelope gene.
  • the hybrid gene encodes an envelope fragment joined to a targeting ligand, whereby the envelope fragment does not facilitate recognition or binding of its normal host cell but does facilitate efficient incorporation of the virus into a mature viral particle, and whereby the targeting ligand facilitates targeting and binding of the mature viral particle to the surface of the heterologous host cell.
  • the method also involves administering the virus so as to permit viral infection of the cell.
  • the invention features a. virus, the genome of which encodes a hybrid envelope protein, wherein the hybrid protein comprises an envelope fragment joined in frame to a targeting ligand, whereby the envelope fragment does not facilitate recognition or binding of its normal host cell but which does facilitate efficient incorporation of the hybrid envelope protein into a mature viral particle and whereby the non-viral protein facilitates targeting and binding of the mature viral particle to the surface of a cell not normally infected by the virus.
  • the invention features a method for % delivering a nucleic acid of interest to a heterologous host cell.
  • the method involves providing a virus that comprises i) the nucleic acid of interest, and ii) a hybrid envelope gene, the hybrid gene encoding an envelope fragment joined to a targeting ligand, whereby the envelope fragment does not facilitate recognition or binding to its normal host cell but does facilitate efficient incorporation of the virus into a mature viral particle, and whereby the targeting ligand facilitates targeting and binding of the mature viral particle to the surface of the heterologous host cell.
  • the method also involves administering the virus so as to permit viral infection of the cell.
  • the virus is an enveloped virus, preferably a Herpesviridae, a Paramyxoviridae, or a Retroviridae, most preferably a Moloney murine leukemia virus, or the virus may also preferably be a Hepadnaviridae, a Poxviridae, or an
  • the virus may be a Togaviridae, a Flaviviridae, a Coronaviridae, a Rhabodoviridae, a Filoviridae, an Orthomyxoviridae, a Bunyaviridae, or an Arenaviridae, or any other, yet unclassified, enveloped virus.
  • the- nucleic acid of interest may include, without limitation, an antisense oncogene; a tumor suppressor gene, e.g., a gene encoding p53, or a gene encoding retinoblastoma protein Rb; a toxin gene, e.g., a diphtheria toxin gene; or a gene encoding a cytokine, e.g., a tumor necrosis factor, or an interferon.
  • the nucleic acid of interest may be either DNA or RNA, e.g., antisense DNA, or antisense RNA, or a nucleic acid encoding an antisense RNA.
  • the nucleic acid of interest may also be a gene invoking intracellular immunity, or a nucleic acid therapeutic for an inherited disease, e.g., an insulin gene, or a cystic fibrosis transmembrane regulator gene.
  • a "gene that invokes intracellular immunity” is a gene that confers a dominant negative resistant phenotype to the cell it is in, thereby protecting the cell against an invading agent.
  • the heterologous host cell may be a cell that has acquired mutations that result in a disease state, preferably a cancer cell, e.g., a colon cancer cell.
  • the heterologous host cell may be a cell infected with a second virus, e.g., a human immunodeficiency virus (HIV), a cell infected with an organism, or an infectious agent such as a bacterium or parasite.
  • the infectious agent may be either unicellular or multicellular.
  • the heterologous host cell may also be a cell affected by a hereditary disease, e.g., a pancreatic beta cell, or a lung cell.
  • the targeting ligand may include a protein, preferably a hormone, or an immunoglobulin, more preferably an anti- tumor associated antigen-specific immunoglobulin, most preferably an anti-carcinoembryonic antigen-specific immunoglobulin, or an anti-HIVgpl20 antigen-specific immunoglobulin.
  • the targeting ligand may also be a carbohydrate, or a lipid.
  • the hybrid envelope fragment may consist of a receptor binding domain, an oligomerization domain, a transmembrane domain, a virus budding domain, sorting signals, a signal sequence, and preferably a fusion domain. In some cases the fusion activity of the envelope fragment may be performed by a second protein.
  • the second protein would therefore direct fusion of the virus with the membrane of the targeted cell.
  • the mode of administration may include, but is not limited to, 1) direct injection of the purified virus; or 2) implanting a container enclosing the virus into a patient.
  • the virus is preferably inside a packaging cell.
  • a "packaging cell” is a cell that supplies viral proteins necessary for production of viral vectors.
  • container is meant a virus permeable enclosure containing virus, or containing packaging cells with virus therein.
  • Normal host cell as used herein, is a cell type commonly infected by the naturally occurring virus.
  • heterologous host cell or a “targeted cell”, as used herein, refers to a cell that is recognized as a function of the targeting ligand portion of the hybrid envelope protein, but is not recognized as a function of the envelope portion of the hybrid envelope protein.
  • targeting ligand is meant a molecule that has binding affinity for a molecule on the surface of a desired targeted cell.
  • a “hybrid envelope protein”, as used herein, is a protein that includes a portion of a viral envelope protein (or a biologically active analog thereof) covalently linked to a targeting ligand.
  • hybrid immunoglobulin-env protein a portion of an immunoglobulin covalently linked to a portion of an envelope protein.
  • a “hybrid envelope gene” is a nucleic acid that provides genetic instructions for a hybrid envelope protein.
  • hybrid anti-careinoe bryonic antigen-specific immunoglobulin is meant a hybrid immunoglobulin-env protein that specifically binds to a carcinoembryonic antigen.
  • fragment includes some but not all of the envelope protein.
  • a fragment will ordinarily be at least about about 20 amino acids, typically at least about 30 amino acids, usually at least about 40 contiguous amino acids, preferably at least about 50 amino acids, and most preferably at least about 60 to 80 or more contiguous amino acids in length. Fragments of an envelope protein can be generated by methods known to those skilled in the art (e.g., those described herein).
  • a biologically active fragment of a viral envelope protein is one that possesses at least one of the following activities: a) it can bind to a cell membrane if given the appropriate targeting ligand; b) it can enable fusion with a cell membrane; or c) it can enable incorporation of proteins into a mature viral particle. These three biological activities can be performed by the same envelope protein fragment, or by two separate envelope protein fragments.
  • the envelope fragments of this invention do not facilitate recognition or binding of the virus' normal host cell. This is accomplished by either destroying the activity of the normal receptor binding region by mutation, or by physically deleting it. A new recombinant receptor- binding region is added in its place.
  • the ability of a candidate fragment to exhibit a biological activity of a viral envelope protein can be assessed by methods known to those skilled in the art.
  • the envelope fragment may include the amino acid sequence of a naturally-ocurring viral envelope or may be a biologically-active analog thereof.
  • the biological activity of an envelope analog is assessed using the methods described herein for testing envelope fragments for activity.
  • Applicants have provided an efficient and reliable means for specifically delivering therapeutic genes or antisense nucleic acids to particular animal, plant or human cell types, or to cells of infectious agents. Their method facilitates treatments for mutagenically acquired, infectious, or inherited diseases, e.g. , by either 1) antagonizing the effect of an existing cellular gene; 2) complementing the defect of an existing cellular gene; 3) destroying the target cells through the introduction of new genetic material; or 4) changing the phenotype of the target cells through the introduction of new genetic material.
  • a hybrid envelope protein e.g., an envelope- antibody or envelope-ligand hybrid
  • the viruses itself, through its efficient internalization mechanisms, facilitates efficient uptake of the therapeutic gene.
  • viral vectors are uniquely adapted to deliver genes, RNA, or drugs to cell surface proteins that do not normally internalize.
  • Another advantage of this invention is that it overcomes the problem of gene regulation encountered with other methods of gene therapy. Genetically-altered cells must not only synthesize the gene products at the right location, at the right time, and in the right amounts, but must also be regulated in the same manner as the indigenous tissue. That is, the transduced cells must also have all the proper signal transduction mechanisms to respond to extracellular signals.
  • fibroblasts do not contain the same receptors and signal transduction machinery as pancreatic beta cells, the insulin genes may be expressed differently. Targeting genes to the right cells insures that the genes will be properly regulated.
  • a selection scheme is devised for creation of hybrid envelope protein-containing, viruses. This strategy will be feasible for env proteins fused with immunoglobulins or with any ligand that recognizes specific receptors on cells.
  • FIG. 1 is a representation of a scheme for constructing retroviral vector pLNCX*.
  • FIG. 2 is a representation of a scheme for constructing plasmid LNCenvpA.
  • FIG. 3 is a representation of a scheme for constructing plasmid LNCenv.
  • FIG. 4 is a representation of a scheme for constructing plasmid pUC Star-Sig.
  • FIG. 5 is a representation of a scheme for constructing plasmid LNC-Sig.
  • FIG. 6 is a representation of a scheme for constructing plasmid LNC-antiCEA.
  • FIG. 7 is a representation of plasmids used in the construction of targeted viruses.
  • FIG. 8 is a representation of a strategy for generating targeted retroviruses involving construction of hybrid immunoglobulin-env genes in vitro.
  • FIG. 9 is a representation of a strategy for generating targeted retroviruses involving generation of pooled virus constructions.
  • FIG. 10 is a representation of a strategy for generating targeted retroviruses involving selection and characterization of targeted virus.
  • FIG. 11 is a representation of a plasmid containing a targeted retroviral vector.
  • FIG. 12 is a representation of a scheme for constructing plasmid pUC Star-antiCEA.
  • FIG. 13 is a representation of an alternative scheme for constructing plasmid LNC-antiCEA.
  • the receptor recognition domain of the viral envelope protein is replaced with a ligand directed against a specific cell surface receptor.
  • the hybrid envelope protein is incorporated into the viral envelope during the budding process, producing a hybrid virus in vivo, upon infection of a host, the hybrid virus specifically recognizes its target cell and resultant fusion with that cell facilitates internalization (into the target cell) of viral genes, including the therapeutic gene(s) which are engineered into the viral genome.
  • Such internalization can be extremely important; for example, immunotoxins, although efficient at delivering toxin molecules to target cells, are often clinically ineffective since the cell surface molecules to which they are targeted do not internalize, and internalization is required for entry of the toxin molecules into the cells (Waldmann, T.A. , 1991, Science 252: 1657-1662) .
  • Targeted viruses circumvent this requirement for receptor internalization since the virus itself contains the necessary cell fusion machinery (Gilbert, J.M. , et al., 1990, J Virol 64: 5106-5113; Roizman, B. et al., 1990, in BN Fields, et al., eds. Virology. Raven Press, Ltd. New York) .
  • targeted viruses are constructed by replacing the receptor recognition domain of the viral envelope protein with a ligand directed against a specific cell surface receptor.
  • the ligand can be, without limitation, an immunoglobulin (e.g., FAb, dAb, Fd, or Fc) , a hormone, or any other synthetic or natural protein that can direct the binding of the targeted viruses to a cell surface molecule.
  • the ligand is biologically incorporated into the viral envelope by genetic fusion with that portion of the normal viral envelope protein involved in viral assembly and budding.
  • the envelope portion of the hybrid protein consists of an envelope fragment (or analog thereof) that is sufficient to direct efficient incorporation of the envelope hybrid protein into the viral envelope.
  • the envelope hybrid protein no longer directs an interaction between the virus and its normal host cell.
  • VSV vesicular stomatitis virus
  • virus envelopes can tolerate changes in length or conformation introduced into the envelope protein, e.g., by a conjugated ligand.
  • Gitman et al have shown that Sendai virus envelopes reconstituted with viral envelope glycoproteins, chemically cross-linked to anti-erythrocyte antibodies acquire the ability to bind to erythrocytes that had been stripped of the normal virus receptor.
  • Sendai virus envelopes reconstituted with envelope proteins, chemically cross-linked to insulin molecules were able to bind to receptor-stripped erythrocytes expressing the insulin receptor. In both cases, envelope binding but not fusion occurred with the receptor-stripped erythrocytes.
  • the targeted virus contains 1) a viral envelope derived from a host cellular membrane; 2) a transmembrane hybrid envelope protein that directs the binding and penetration of the virus to specific target cells; 3) a transmembrane envelope protein that directs the fusion of the targeted virus with the cellular membrane of the targeted cell for viral penetration (e.g., the targeting protein itself or another envelope protein) ; 4) viral core proteins; 5) a foreign gene(s) of interest; and 6) all necessary viral and genetic components for penetration and expression of genes contained in the viral genome.
  • the transmembrane hybrid' envelope protein consists of 1) determinants that enable the hybrid protein to become processed and incorporated into viral envelopes; 2) determinants that enable fusion of the viral envelope with the targeted cellular membrane; these are essential for penetration of the targeted virus; 3) a ligand determinant that enables the targeted virus to recognize and bind to specific receptors on target cells.
  • the viral genome may also include bacterial selectable markers (e.g., ampicillin resistance) and/or a mammalian cell selectable marker (e.g., neomycin resistance).
  • the transmembrane hybrid protein is constructed genetically by splicing the cell surface receptor binding domain of a ligand gene to a portion of the viral envelope protein gene.
  • the transmembrane hybrid protein must retain those portions of the envelope protein that direct the efficient post-translational processing, sorting and incorporation of the protein into the viral envelope.
  • the receptor binding domain is that portion of the envelope protein that recognizes and binds to cell surface receptors. In hybrid envelope proteins, this portion of the envelope protein is replaced with ligand sequences.
  • the receptor binding domain of retrovirus envelope proteins has been localized to the SU subunit (Coffin, J.M. , 1990, in BN Fields, et al., eds. Virology r Raven Press, Ltd., New York). Since the SU protein of retroviruses is coded for 5' to the transmembrane protein, replacement of the amino-terminal sequences of the envelope protein with ligand sequences poses no problem for the creation of a functional hybrid ligand- envelope protein.
  • the envelope protein of retroviruses is synthesized as a polyprotein which is later proteolytically cleaved to form SU and TM heterodimers.
  • the proteolytic cleavage site should be eliminated.
  • the proteolytic cleavage site should be eliminated either by deletion or by site directed mutagenesis. Perez and Hunter have demonstrated that elimination of the . proteolytic cleavage site does not block transport or surface expression of Rous sarcoma virus envelope proteins (Perez, L.G., et al. , 1987, J Virol 61:1609- 1614) .
  • trimerization of the envelope protein is thought to be essential for the proper transport and insertion of envelope proteins into the viral envelope (Singh, J. et al., 1990, Embo J 9.:631-639; Kreis, T.E., et al., 1986, Cell 46.:929-937) . Therefore it is important that this domain be retained in the hybrid ligand-envelope protein.
  • the trimerization domain likely resides in the transmembrane TM protein of retroviruses (Einfeld, D.
  • the fusion domain is a hydrophobic stretch of amino acids that is involved in fusion of the virus envelope with the cell membrane (Wiley, D.C., et al., 1990, in Fields, B.N. et al., eds. Virology r 2nd ed. , Raven Press, Ltd., New York). Viral fusion allows entry of the viral core proteins and genome into the cell.
  • influenza virus the fusion domain, located in the amino terminus of the envelope HA2 protein, is sequestered in the hemagglutinin trimer until a low pH-induced conformational change allows presentation of the fusion domain to the cell membrane.
  • Trimerization of the envelope proteins can prevent constitutive expression of fusion activity by sequestering it within an internal hydrophobic pocket.
  • a potential fusion domain has been located within the extracellular portion of the gp37 TM protein of Rous sarcoma virus (Hunter E. et al., 1983, J Virol __ y.920-936) .
  • Similar hydrophobic fusion sequences have been noted in the pl5E protein of Moloney murine leukemia virus (Mo-MuLV) (Chambers, P., et al.,1990, J Gen Virol 71:3075-3080).
  • the first protein is the hybrid ligand-envelope protein which directs targeting of the virus but lacks fusion activity.
  • the second protein is an envelope protein possessing fusion activity but lacking a receptor binding domain. This type of situation is observed for paramyxoviruses where one envelope protein is dedicated to targeting while another carries out fusion (Kingsbury, D.W. , 1990, B.N. Fields, et al., eds. Virology, 2nd ed. , Raven Press, Ltd., New York.). Where it is not necessary to prevent constitutive fusion activity, both activities may be included in one protein. 5. Transmembrane domain
  • the transmembrane domain is a stretch of approximately twenty or more amino acids that anchor the envelope protein to the viral envelope. It is located within the pl5E protein of Moloney murine leukemia virus (Chambers, et al., supra) . Retention of the transmembrane domain is thought to be essential since deletion of the transmembrane domain results in secretion of the synthesized envelope protein (Perez, L.G., et al., 1987, J Virol 11:2981-2988). 6. Virus budding domain
  • Amino acid sequences within the envelope protein may be involved with the exclusive incorporation of viral envelope proteins into viral envelopes and with virus budding.
  • the virus budding domain directs the hybrid ligand-envelope protein into the viral envelope. These sequences are thought to reside within the portion of the envelope protein facing the inside of the virus and may involve specific protein-protein interactions between envelope proteins and viral core or matrix proteins.
  • Sorting signals are determinants that direct the envelope protein to the correct intracellular location during post-translational processing. These sequences insure that the envelope protein passes through the endoplasmic reticulum, Golgi apparatus, and other ⁇ rganelles until it eventually reaches the viral envelope. Other signals that may have to be retained in the hybrid ligand-envelope protein are glycosylation sequences and sequences involved in effective conformation of the envelope protein (e.g., disulfide bonds) .
  • the signal sequence is an amino-terminal hydrophobic stretch of amino acids that directs the envelope protein into the endoplasmic reticulum.
  • the signal sequence which is later proteolytically cleaved. is essential for the hybrid ligand-envelope protein to become located in a membrane.
  • the diversity of signals and domains that must be considered in constructing targeted viruses requires that precise and correct splicing of ligand and envelope genes occur.
  • the present invention describes a selection scheme for constructing targeted viruses whereby the ligand gene is spliced to an envelope gene fragment; this hybrid gene codes for those portions of the envelope protein which are required to direct efficient incorporation of the resultant hybrid envelope-ligand protein into the mature viral particle.
  • cell surface receptor binding domains of ligand genes are randomly ligated to progressive deletions of viral envelope genes.
  • the correct combination of ligand and envelope sequences is determined by a selection scheme for the production of biologically active targeted virus. The selection scheme not only produces targeted virus but simplifies the construction of future targeted viruses.
  • a Specific Example of a Targeted Retrovirus There now follows an example of a recombinant retrovirus which targets and infects particular host cells for the purpose of delivering to those cells a desired therapeutic gene.
  • This example is provided for the purpose of illustrating, not limiting, the invention.
  • Moloney murine leukemia virus (Mo-MuLV) is a mouse ecotropic retrovirus.
  • a recombinant Mo-MuLV based retroviral vector that is targeted to colon cancer cells is constructed.
  • the targeted retroviral vector delivers the neomycin resistance gene to colon cancer cells.
  • Targeting to human colon cancer cells is accomplished by incorporating into the viral envelope hybrid immunoglobulin-env proteins directed against carcinoembryonic antigen.
  • Carcinoembryonic antigen is a tumor associated antigen expressed on the surface of human colon cancer cells but not on the surface of normal adult cells.
  • the CEA glycoprotein possessing multiple membrane spanning alpha helices, does not internalize in response to ligand (Benchimol, S. et al., 1989, Cell 57:327-334).
  • a protein that is homologous to carcinoembryonic antigen has recently been shown to be the receptor for mouse hepatitis virus (Dveksler, G.S., et al, 1991, J Virol 65.:6881-6891) .
  • a single variable region of the heavy chain of anti-CEA is fused to a portion of the env gene.
  • dAb Single variable heavy chain fragments
  • Fb fragmented antibodies
  • dAb's Single variable heavy chain fragments
  • monoclonal antibodies Ward, E.S., et al.. Nature 341:544-546.
  • the function of immunoglobulin-env proteins is not limited, however, to the use of dAb's and can be applied with FAb's, Fv's and mAb's. Modification of the retroviral vector LNCX
  • LNCX is a Moloney murine leukemia virus based retroviral vector contained in the plasmid pLNCX (Miller, A.D., et al., 1989, Biotechniques 2:980-990).
  • pLNCX contains a unique Hindlll and Clal cloning site for expression of inserted genes, a cytomegalovirus (CMV) promoter, a polyadenylation site (pA) , retroviral long terminal repeats (LTR) for retroviral RNA transcription and reverse transcription, a bacterial neomycin resistance gene (Neo) which conveys resistance to both neomycin and G418, a bacterial origin of replication
  • CMV cytomegalovirus
  • pA polyadenylation site
  • LTR retroviral long terminal repeats
  • Neo bacterial neomycin resistance gene
  • LNCX is modified to contain a unique Sail site as shown in Figure 1.
  • pLNCX is linearized with Xbal and subcloned into the Xbal site of the phagemid Bluescriptll SK+ (Stratagene, La Jolla, CA) .
  • Single stranded DNA is purified and the unique BstEII site of LNCX is converted into a Sail site by site directed mutagenesis with the oligonucleotide 5'-GCAGAAGGTCGACCCAACG-3' (SEQ ID NO: 1).
  • the BstEII site is located within the extended packaging signal ( ⁇ +) of Mo-MuLV RNA (Bender, M.A. , et al., 1987, J Virol 61:1639-1646; Adam, M.A., et al., 1988, J Virol 62:3802- 3806; Armentano, D. et al., 1987, J Virol 61:1647-1650) .
  • Conversion of the BstEII site to Sail does not affect packaging since this region has been determined to be dispensable for efficient packaging (Schwartzberg. P., et al., 1983, J Virol 46:538-546; Mann R.
  • the BstEII site is converted into a Sail site because BstEII sites, but not Sail sites, frequently occur in heavy chain genes (Chaudhary, V.K. , et al, 1990, Proc Natl Acad Sci USA 82:1066-1070).
  • the Sail containing plasmid is recircularized with Xbal and DNA ligase to form the plasmid pLNCX*.
  • the Mo-MuLV env gene is cloned into pLNCX*. as shown in Figure 2.
  • the Mo-MuLV env gene is excised from plasmid p8.2 (Shoemaker, C. , et al., 1980, Proc Natl Acad Sci USA 22:3932-3936) as a 1.9kb Scal-Nhel fragment.
  • the 1.9kb Scal-Nhel fragment contains the entire coding region for the pl5E transmembrane protein and the majority of the coding region for the gp70 SU protein.
  • the 5'-protruding ends are digested with Sl-nuclease, and Hindlll linkers (5-CCAAGCTTGG-3'; SEQ ID NO: 2) are added.
  • the env gene is cloned as a Hindlll fragment in the Hindlll site of pLNCX* to form plasmid LNCenvpA.
  • the orientation of the Hindlll env fragment is such that it can be transcribed and expressed from the cytomegalovirus (CMV) promoter. Modification of LNCenvpA to LNCenv
  • LNCenvpA is cloned as an Xbal fragment in phagemid pBluescript II SK+ for additional site directed mutagenesis ( Figure 3) .
  • the env encoding Hindlll fragment contains a polyadenylation signal that may interfere with the polyadenylation signal provided by the viral vector.
  • the AAUAAA polyadenylation signal is therefore changed to AAGAAA by site directed mutagenesis with the oligonucleotide 5'-GTTTTCTTTTATC-3' (SEQ ID NO: 3) .
  • the Hindlll site located at the 3' end of the env gene is eliminated by site directed mutagenesis with the oligonucleotide 5-CAAGCATGGCTTGCC-3' (SEQ ID NO: 4).
  • the env containing retroviral vector is re ⁇ ircularized by Xbal restriction and ligation to form plasmid LNCenv.
  • Molecular cloning of anti-CEA immunoglobulin genes cDNA encoding the mature variable region domain of anti-CEA heavy chain genes is cloned as an Xhol-Spel fragment using the polymerase chain reaction (PCR) and RNA template.
  • RNA is derived from the spleen of mice immunized against purified carcinoembryonic antigen.
  • RNA can be derived from hybridoma cell lines that secrete monoclonal antibodies against CEA, e.g., 1116NS-3d (American Type Culture Collection CRL8019) or CEA 66-E3 (Wagener, C, et al., 1983, J Immunol 130:2308-2315) .
  • the following PCR primers hybridize to cDNA encoding the aminoterminal end of mature heavy chain genes (Stratacyte, Inc.).
  • the degenerate primers introduce an Xhol site which is underlined. 5' AGGTGCAGCTGCTCGAGTCGGG 3' (SEQ ID NO: 5)
  • ImmunoZAP H is a modified lambdaZAP vector that has been modified to express in E.coli immunoglobulin variable heavy chain fragments behind a pelB signal sequence. The procedure could similarly be performed by expressing immunoglobulin variable light chain fragments in a packaging cell line. Identification of high affinity anti-CEA clones Clones expressing high affinity anti-CEA antibodies are identified by a filter binding assay.
  • the anti-CEA phage library is screened by nitrocellulose plaque lifts with [ 125 I]bovine serum albumin conjugated to CEA, as previously described (Huse, W.D., et al., 1989, Science 146:1275-1281). High and intermediate affinity anti-CEA clones are chosen for further manipulation. Construction of plasmid LNC-itnmuno ⁇ loj ulin
  • LNC-antiCEA which codes for an anti-CEA immunoglobulin gene
  • LNC- immunoglobulin vectors encode an immunoglobulin peptide fused to an amino-terminal signal sequence. Some-amino acids at the amino-terminal end of the mature immunoglobulin peptide have been modified by the PCR primers used to generate the immunoZAP library.
  • the design of the LNC-antiCEA plasmid results in the insertion of an extra amino acid at the amino terminal end.
  • amino acid changes do not affect antigen binding because 1) the amino acid changes are conservative; 2) the affected amino acids are normally variable at those sites; and 3) the affected amino acids occur within the framework region of immunoglobulins which has been shown not to participate in antigen binding or conformation of the antibody (Relchman et al. 1988 Nature 332:323-327) . It is for these same reasons that cleavage of the signal sequence from mature peptide will not be affected.
  • pUC119 is a phagemid containing a polylinker cloning site.
  • the multiple cloning sites of pUC119 are replaced with new restriction sites by insertion of the following polylinker into the Hindlll and Xbal sites of pUC119.
  • the modified pUC119 is called pUC Star-1 ( Figure 4) .
  • the restriction sites may be further separated by small linkers, if adjacent restriction sites interfere with one another during digestion.
  • the signal sequence from an anti-NP immunoglobulin heavy chain gene is isolated from plasmid pcDFL.l (Ucker, D.S., et al., 1985, J Immnol JL35:4204-4214) as a ⁇ 330bp PstI fragment.
  • the 330bp PstI fragment is subcloned into pUC Star-1 to yield plasmid pUC Star-Sig ( Figure 4).
  • the PstI fragment is oriented so that the signal sequence can be expressed.
  • LNCX* is converted into a eukaryotic immunoglobulin expression vector ( Figures 4 and 5) .
  • An immunoglobulin heavy chain signal sequence and Xhol-Spel cloning sites are inserted behind the CMV promoter of plasmid LNCX* to allow expression of the PCR amplified immunoglobulin genes.
  • Conversion of LNCX* is as follows. The immunoglobulin heavy chain signal sequence is recovered from pUC Star-Sig as a Hindlll-Clal restriction fragment and cloned into the Hindlll-Clal sites of LNCX*.
  • the resulting plasmid, LNC-Sigr contains a retroviral vector with the immunoglobulin heavy chain signal sequence under control of the CMV promoter ( Figure 5) .
  • An anti-CEA gene from the immunoZAP library is then subcloned into LNC-Sig to form plasmid LNCanti-CEA.
  • This generates an anti-CEA variable heavy chain gene containing a signal sequence ( Figure 6).
  • the anti-CEA gene is first excised from immunoZAP phage DNA as a Bluescript SK- phagemid (see lambdaZAP protocols, Stratagene, Inc. La Jolla, CA) .
  • the anti-CEA gene is purified as an Xhol-Spel fragment and ligated to Xhol- Spel restricted LNC-Sig.
  • LNC-Sig contains three Spel sites. Therefore, to generate plasmid LNCanti-CEA, the ligation mix is transformed into neomycin-sensitive, ampicillin-sensitive E__ coli and neomycin-resistant, ampicillin-resistant transformants are selected for. Plasmid LNCanti-CEA is screened from neomycin-resistant, ampicillin-resistant transformants by using the Spel-Xhol anti-CEA restriction fragment from Bluescript SK-anti-CEA as a probe. The Spel site is used because of dependence upon the available sites in the ImmunoZap expression vector. To simplify construction of LNCanti-CEA, a unique NotI site can be introduced into the ImmunoZap H expression vector so that NotI sites can be used instead of Spel sites.
  • An anti-CEA gene from the immunoZAP library is subcloned into plasmid pUC Star-Sig to form plasmid pUC Star-anti-CEA. This generates an anti-CEA variable heavy chain gene containing a signal sequence ( Figure 12) .
  • the anti-CEA gene is excised from immunoZAP phage DNA as a Bluescript SK-phagemid (see lambdaZAP protocols, Stratagene, Inc., La Jolla, CA) . Bluescript SK-anti-CEA double stranded DNA is prepared and restricted with Xhol and Spel.
  • the anti-CEA containing Xhol-Spel fragment is purified by electroelution and ligated to Xho-Spel restricted pUC Star-Sig to create plasmid pUC Star- antiCEA ( Figure 12) .
  • the antiCEA gene is transferred from pUC Star-anti CEA to LNCX* as a Hindlll-Clal fragment to create plasmid LNC-antiCEA (figure 13) .
  • the antiCEA-containing Hindlll- Clal fragment is purified from pUC Star-antiCEA by electroelution. Phosphatase treated, Hindlll-Clal restricted LNCX* is ligated with the purified Hindlll- Clal antiCEA fragment to generate LNC-antiCEA (figure 13) .
  • LNCenv and LNC-immunoglobulin in this example, LNC-antiCEA
  • Figures 8-11 diagram the general principle for the primary generation of targeted viruses.
  • Hybrid immunoglobulin-env proteins are generated that target viruses to cells expressing carcinoembryonic antigen. Since the location of important determinants for envelope protein sorting (S) , trimerization (T) , and fusion (F) is not known with certainty, the immunoglobulin gene is ligated to progressive deletions of the env gene and functional immunoglobulin-env hybrids are selected for.
  • the envelope portion of the fusion protein may consist of any portion of the envelope protein (or any analog thereof) which is sufficient to direct efficient incorporation of the envelope fusion protein into the viral coat (upon budding of the recombinant virus from a producer cell line) .
  • Such fragments or analogs may be determined using the following general selection scheme which generally involves ligation of cell surface receptor binding domains of ligand genes to progessive deletions of viral envelope genes.
  • the correct combination of ligand and envelope sequences is determined by a selection scheme for the production of biologically active targeted virus. The selection scheme not only produces targeted virus but simplifies the construction of future targeted viruses.
  • LNCenv contains the coding region for the Mo-MuLV env polyprotein ( Figure 8) .
  • LNCenv is first linearized by Hindlll restriction. A range of deletions extending into the env gene is created by collecting aliquots of Exonuclease III treated DNA over time and removing 5'-processive ends with Sl-nuclease (Guo, I.H., et al., 1983, Methods Enzymol 100:60; and Sambrook, J. , et al., 1989, Molecular Cloning. Cold Spring Harbor Laboratory Press, Cold Spring Harbor) .
  • NotI linkers (5' AGCGGCCGCT 3' SEQ ID NO: 13) are ligated onto the blunt end termini and restricted with NotI. This results in a NotI restriction overhang at the 5'-border of every deletion within the env gene. The NotI overhangs at the other end of the molecules are removed by Sail restriction of the reaction mixture. The reaction mixture is then treated with phosphatase to prevent circularization of the reaction products. The reaction mixture is ligated to a Sall-NotI restriction fragment from LNC-antiCEA that contains the anti-CEA variable heavy chain gene. This creates a pool of functional retroviral vectors encoding an anti-CEA peptide fused to a series of env deletions. Generation of pooled virus constructions
  • the total reaction mixture from above is transformed into ampicillin-sensitive E. coli and ampicillin resistance is selected for ( Figure 9) .
  • Re ⁇ ombinants containing functional retroviral vectors are selected for since only they contain the ampicillin resistance gene.
  • Plasmid DNA is prepared from transformants grown in liquid culture to create a pool of retroviral vectors containing different immunoglobulin- env fusion genes.
  • the DNA is transfected into the crip2 retroviral packaging cell line (Danos, 0., et al., 1988, Proc Natl Acad Sci USA 85: 6460-6464) .
  • DNA is transfected into a packaging cell line that does not encode wild-type env protein.
  • the transfected packaging cell line synthesizes each of the different hybrid immunoglobulin-env proteins as well as the wild type env protein (encoded by an env gene contained in the cell line) .
  • the transfected packaging cell line secretes a pool of enveloped retroviruses containing the different retroviral genomes encoding hybrid immunoglobulin-env genes. If the hybrid immunoglobulin-env protein retained all of the necessary determinants for efficient incorporation into viral envelopes then the hybrid-env protein can be incorporated into viral envelopes. Wild type env proteins encoded for by the packaging cell line are also incorporated into the viral envelopes. This creates a virus containing both wild type and hybrid env proteins in the viral envelope.
  • This system therefore selects for immunoglobulin-env hybrids that can incorporate their gene products into the viral envelope.
  • Virus pools are harvested from media filtered at 0.45 ⁇ to remove contaminating G418-resistant packaging cells. Selection and characterization of targeted virus G418-sensitive target cells are exposed to virus pools by standard procedures, and G418-resistant cells are selected for.
  • the target cells can be any non-mouse cell line (uninfe ⁇ table by wild type Mo-MuLV) that expresses carcinoembryonic antigen.
  • ATCC COLO 205 a human cell line isolated from the ascites of a patient with carcinoma of the colon (A.T.C.C.#CCL 222); LR-73 CEA, a Chinese hamster ovary cell line transfected with a mouse carcinoembryonic antigen gene (Benchimol, S. et al., supra) ; and HCT48, a human colon adenocarcinoma cell line (Shi, Z.R., et al., 1883, Cancer Res 11:4045-4049).
  • G418-resistant cells can only have arisen from transduction of the neomycin resistance gene by targeted virus. This system therefore selects for recombinant viruses that have hybrid immunoglobulin-env proteins that have retained all the necessary determinants for viral targeting and fusion. Rescue of integrated immunoglobulin-env gene
  • PCR polymerase chain reaction
  • PCR 5' Rescue primer 5 '-CCAGCCTCCGCGGCCCCAAGCTTCTGCA-3' (SEQ ID NO: 14)
  • the retroviral vector produced in the above selection scheme is targeted to both CEA-expressing human cells (directed by the hybrid envelope protein) and normal mouse cells (directed by the wild type envelope protein) when produced in crip2 packaging cells.
  • the retroviral vector will irst be tested to determine if incorporation of the hybrid envelope protein alone is sufficient to direct virus fusion. This is accomplished by transfecting DNA into a modified packaging cell line that does not encode wild type env.
  • targeted viruses will be created as follows.
  • a packaging cell line will be created that encodes an env gene containing mutations in the receptor binding domain.
  • targeted viruses expressing both hybrid ligand-env proteins and env proteins with mutated binding sites will be produced.
  • the viruses will exclusively infect target cells.
  • the targeted viral vector is a universal vector
  • the viral vector that is constructed by the above procedure is a universal targeted vector ( Figure 11) .
  • Targeting to other cells is accomplished by replacing the Xhol-Spel anti-CEA fragment with any Xhol-Spel fragment encoding an in-frame immunoglobulin or ligand directed against specific cell surface proteins.
  • an Xhol-Spel immunoglobulin-containing fragment from an immunoZAP library can be fused in frame behind a signal sequence and subcloned into LNCX* through the pUC Star- Sig plasmid, as outlined above. Substituting a Sall-NotI fragment from another LNC-immunoglobulin plasmid into the universal vector would create another targeted virus vector.
  • Any enveloped virus may be used as a vector for the targeted delivery of a therapeutic gene.
  • Particular examples include both DNA and RNA viruses, such as Herpesviridae, e.g., herpes simplex type 1 or 2, Paramyxoviridae, Retroviridae, Hepadnaviridae, Poxviridae, Iridoviridae, Togaviridae, Flaviviridae, Coronaviridae, Rhabodoviridae, Filoviridae, Orthomyxoviridae, Bunyaviridae, or Arenaviridae, or any other, yet unclassified, enveloped virus.
  • Herpesviridae e.g., herpes simplex type 1 or 2, Paramyxoviridae, Retroviridae, Hepadnaviridae, Poxviridae, Iridoviridae, Togaviridae, Flaviviridae, Coronaviridae, Rhabodoviridae, Filovirid
  • any molecule that is capable of directing specific interaction with a target host cell may be used as the targeting ligand portion of the envelope fusion protein.
  • a target host cell e.g., by specific recognition of and binding to a host cell surface protein
  • a protein is derived from one member of a ligand:receptor pair.
  • the targeting ligands are not limited to proteins. Carbohydrate and lipid moieties can be attached to the envelope protein via protein fragments containing consensus sequences for glycosylation and lipidation.
  • Immunoglobulin genes can be used as ligands, as shown in the example above. Genes for high affinity immunoglobulins are screened from a lambda or bacterial expression library by a filter binding assay with [ 125 I] bovive serum albumin conjugated to antigen, as previously described (Huse, et al. Supra) .
  • Cell surface molecules such as integrins, adhesion molecules or homing receptors can be used as cell- specific ligands since they are involved in cell-cell interactions via receptors on other cells. Genes encoding these molecules can be identified by the panning method of Seed and Aruffo (Seed. B., et al., 1987, Proc Natl Acad Sci USA 84:3365-3369) .
  • Hormones that bind to specific receptors can be used as targeting ligands as well as viral proteins, such as HIV envelope protein gpl20, and modifications of naturally occuring ligands.
  • Therapeutic Genes can be used as targeting ligands as well as viral proteins, such as HIV envelope protein gpl20, and modifications of naturally occuring ligands.
  • Therapeutic genes useful in the invention include the following. 1) Genes that are therapeutic to cancer cells may include a) antisense oncogenes; b) tumor suppressor genes, such as p53 or the retinoblastoma gene product Rb, c) destructive toxin genes such as a diphtheria toxin gene; d) cytokines such as tumor necrosis factor or interferons; or e) any other therapeutic gene. 2) Therapeutic genes targeted to cells that are infected with HIV.
  • antisense DNA complementary to essential genes for HIV e.g., polymerase
  • destructive toxin genes- e.g., diphtheria toxin
  • genes that will invoke intracellular immunity e.g., HIV enhancer sequences that titrate and remove HIV regulatory proteins (Baltimore, D., 1988, Nature 335:395-396) .
  • HIV enhancer sequences that titrate and remove HIV regulatory proteins (Baltimore, D., 1988, Nature 335:395-396) . 3) Genes to correct inherited deficiencies. Examples include, but are not limited to, insulin genes delivered specifically to pancreatic beta cells, or the cystic fibrosis transmembrane regulator (CFTR) gene delivered to the appropriate lung cells of cystic fibrosis patients.
  • the expression of targeted genes can be further accomplished through the use of tissue specific enhancers that regulate the transgene.
  • the appropriate recombinant virus is administered to a patient in a pharmaceutically- acceptable buffer (e.g., physiological saline).
  • a pharmaceutically- acceptable buffer e.g., physiological saline.
  • the therapeutic preparation is administered in accordance with the condition to be treated.
  • the virus is administered by direct injection, e.g., by intravenous, intramuscular, or intraperitoneal injection, at a dosage that provides suitable targeting and lysis of HIV-infected host cells.
  • an appropriate dosage is an amount of therapeutic virus which effects a reduction in the disease.
  • Targeted virus can also be administered by implanting viral packaging cells into a patient.
  • the cells can be enclosed in a semi-permeable container, e.g., permeable to a virus but not permeable to a packaging cell.
  • the implanted container may be removable.
  • the container may be hooked up to a patient intravenously, so that virus enters the patient through a needle or through a catheter. In this way the patient receives a continuous dose of viral gene therapy.
  • replication competent viruses may be used in certain cases.
  • modified packaging cells rather than the targeted virus
  • a non-proliferating dose of recombinant virus is delivered to a local area, and then the virus locates the specific target cell.
  • TIL tumor infiltrating lymphocytes
  • Treatment may be repeated as necessary. Immune response against targeted viruses can be overcome with immunosuppressive drugs.
  • the virus of the invention may be used to target other cancer cells, e.g., ovarian, breast, or lung cancer cells, or cells affected with hereditary diseases such as muscular dystrophy, Huntington's disease, or cells with a defect in adenosine deaminase.
  • Herpesviridae viruses may include Herpes simplex type 1 or type 2, Epstein-Barr virus, or Cytomegalovirus. Sendai virus and Vaccinia virus may also be adapted to this method.

Abstract

L'invention se rapporte à un procédé général pour introduire des gènes dans des cellules cibles spécifiques in vivo. A cet effet, on modifie par génie génétique des virus enveloppés, afin d'infecter les cellules cibles spécifiques en remplaçant le domaine de reconnaissance des récepteurs de surface cellulaire des protéines d'enveloppe virale par des ligands qui dirigent la fixation et la fusion de ces virus sur des molécules de surface de ces cellules spécifiques.
EP93908659A 1992-04-03 1993-03-31 Therapie genique utilisant des vecteurs viraux cibles. Withdrawn EP0633943A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40748 1979-05-21
US86279592A 1992-04-03 1992-04-03
US862795 1992-04-03
US4074893A 1993-03-29 1993-03-29
PCT/US1993/002957 WO1993020221A1 (fr) 1992-04-03 1993-03-31 Therapie genique utilisant des vecteurs viraux cibles

Publications (2)

Publication Number Publication Date
EP0633943A1 true EP0633943A1 (fr) 1995-01-18
EP0633943A4 EP0633943A4 (fr) 1997-05-02

Family

ID=26717389

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93908659A Withdrawn EP0633943A4 (fr) 1992-04-03 1993-03-31 Therapie genique utilisant des vecteurs viraux cibles.

Country Status (5)

Country Link
EP (1) EP0633943A4 (fr)
JP (1) JPH07505773A (fr)
AU (1) AU3940293A (fr)
CA (1) CA2133411A1 (fr)
WO (1) WO1993020221A1 (fr)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643756A (en) * 1992-08-28 1997-07-01 The Public Health Research Institute Of The City Of New York, Inc. Fusion glycoproteins
US5723287A (en) * 1992-09-22 1998-03-03 Medical Research Council Recombinant viruses displaying a nonviral polypeptide on their external surface
EP0746625B1 (fr) * 1992-11-09 2004-03-31 THE UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Particules vectorielles pouvant etre ciblees
DE69520496T2 (de) * 1994-05-13 2001-07-12 Chiron Corp Verfahren und zusammensetzungen als vehikel zur zielgerichtete einbringen von genen
US5753499A (en) * 1994-12-23 1998-05-19 New York University Viral vector complexes having adapters of predefined valence
JP2001519647A (ja) * 1995-12-28 2001-10-23 カイロン コーポレイション 標的細胞中へのウイルスおよび粒子の取り込みおよびインターナリゼーションのためのレセプター特異的キメラウイルス表面ポリペプチド
US6392069B2 (en) 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US7002027B1 (en) 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6140305A (en) 1996-04-04 2000-10-31 Bio-Rad Laboratories, Inc. Hereditary hemochromatosis gene products
US7026116B1 (en) 1996-04-04 2006-04-11 Bio-Rad Laboratories, Inc. Polymorphisms in the region of the human hemochromatosis gene
US6849399B1 (en) 1996-05-23 2005-02-01 Bio-Rad Laboratories, Inc. Methods and compositions for diagnosis and treatment of iron misregulation diseases
US6319504B1 (en) 1996-06-24 2001-11-20 University Of Maryland Biotechnology Institute Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin
KR100336551B1 (ko) 1996-11-15 2002-05-11 이. 엘. 나가부샨, 리차드 비. 머피 망막아종 단백질의 조직 특이적 발현
US6074850A (en) * 1996-11-15 2000-06-13 Canji, Inc. Retinoblastoma fusion polypeptides
US6432699B1 (en) 1997-03-28 2002-08-13 New York University Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A
ES2303726T3 (es) 1997-04-10 2008-08-16 University Of Southern California Proteinas modificadas que se fijan a componentes de la matriz extracelular.
US6004798A (en) * 1997-05-14 1999-12-21 University Of Southern California Retroviral envelopes having modified hypervariable polyproline regions
ATE525477T1 (de) 1998-03-30 2011-10-15 Northwest Biotherapeutics Inc Therapeutische und diagnostische anwendungen welche auf der rolle von cxcr-4 in der tumorgenese basieren
AU753995B2 (en) 1998-04-07 2002-10-31 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
US6777388B1 (en) 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
DE19904800C1 (de) 1999-02-05 2001-02-08 Eberhard Hildt Partikel zur Gentherapie
JP2000279178A (ja) * 1999-02-24 2000-10-10 Japan Found Cancer Res ウイルスベクター
EP2357192A1 (fr) 1999-02-26 2011-08-17 Human Genome Sciences, Inc. Endokine alpha humain et methodes d'utilisation
US6759393B1 (en) 1999-04-12 2004-07-06 Pfizer Inc. Growth hormone and growth hormone releasing hormone compositions
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
AU5011400A (en) 1999-05-14 2000-12-05 Arbor Vita Corporation Molecular interactions in t cells
DE60035218D1 (de) 1999-11-18 2007-07-26 Dendreon Corp Nukleinsäuren, welche für endotheliasen kodieren, endotheliasen, sowie deren verwendung
NZ519217A (en) 1999-12-10 2004-03-26 Invitrogen Corp Use of multiple recombination sites with unique specificity in recombinational cloning
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
EP2431054A3 (fr) 2000-06-15 2013-03-06 Human Genome Sciences, Inc. Facteur delta de nécrose de tumeur humaine et epsilon
AU6842701A (en) 2000-06-16 2002-01-14 Human Genome Sciences Inc Antibodies that immunospecifically bind to blys
EP1967205B1 (fr) 2000-08-30 2012-10-10 Pfizer Products Inc. Anti-IgE vaccins
EP2338512A1 (fr) 2000-11-28 2011-06-29 MedImmune, LLC Procédés d'administration/dosage d'anticorps anti-rsv pour la prophylaxie et le traitement
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
ATE470676T1 (de) 2001-04-13 2010-06-15 Human Genome Sciences Inc Anti-vegf-2 antikörper
FI116851B (fi) 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
JP2003047482A (ja) 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性ＩｇＥワクチン
CN100594935C (zh) 2001-05-25 2010-03-24 人体基因组科学有限公司 免疫特异性结合trail受体的抗体
EP1404842A2 (fr) 2001-06-29 2004-04-07 Novartis AG Methode de criblage de perv et son utilisation
WO2003046176A2 (fr) 2001-11-26 2003-06-05 Hybrigenics Interactions entre proteines dans le vih
EP1499352A4 (fr) 2002-04-12 2006-10-11 Medimmune Inc Anticorps anti-interleukine-9 recombinants
ES2443416T3 (es) * 2002-07-18 2014-02-19 Helix Biopharma Corp. Uso de ureasa para inhibir el crecimiento de células cancerosas
JP4459810B2 (ja) 2002-08-14 2010-04-28 マクロジェニクス，インコーポレーテッド ＦｃγＲＩＩＢ特異的抗体とその利用法
EP1636248A4 (fr) 2002-12-16 2006-09-06 Halozyme Inc Glycoproteine de chondroitinase (chasegp) humaine, son procede de preparation et compositions pharmaceutiques comprenant ladite glycoproteine
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
WO2004071462A2 (fr) 2003-02-12 2004-08-26 Johns Hopkins University Procede et composition pour le traitement d'infections virales utilisant l'interaction tsg101-vps28
DK2163643T3 (en) 2003-03-05 2015-03-23 Halozyme Inc Soluble hyaluronidaseglycoprotein (sHASEGP), process for preparing the same, pharmaceutical compositions and uses thereof covered
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US7354584B2 (en) 2003-04-11 2008-04-08 Medimmune, Inc. Recombinant IL-9 antibodies
KR101202974B1 (ko) 2003-06-13 2012-11-21 유니버시티 오브 메디신 앤드 덴티스트리 오브 뉴 저지 Ｒｎａ 인터페라제 및 이의 사용 방법
AU2004259727A1 (en) 2003-07-15 2005-02-03 Barros Research Institute Compositions and methods for immunotherapy of cancer and infectious diseases.
JP2007511738A (ja) 2003-08-08 2007-05-10 ジーンニュース インコーポレーテッド 変形性関節症のバイオマーカー及びその使用
ES2458636T3 (es) 2003-08-18 2014-05-06 Medimmune, Llc Humanización de anticuerpos
WO2005032572A2 (fr) 2003-10-03 2005-04-14 Vib Vzw Moyens et procedes de recrutement et d'identification de celles souches
US20050227251A1 (en) 2003-10-23 2005-10-13 Robert Darnell Method of purifying RNA binding protein-RNA complexes
EP1692262B1 (fr) 2003-10-27 2018-08-15 Merck Sharp & Dohme Corp. Procede pour designer des arnsi pour l'extinction de genes
DK1711528T3 (da) 2003-12-23 2012-08-20 Genentech Inc Behandling af cancer med hidtil ukendte anti-il 13 monoklonale antistoffer
WO2005097184A2 (fr) 2004-03-26 2005-10-20 Human Genome Sciences, Inc. Anticorps contre le recepteur nogo
WO2006001888A2 (fr) 2004-04-16 2006-01-05 Acuity Pharmaceuticals Inc Compositions et procedes permettant d'inhiber l'angiogenese
US10066268B2 (en) 2004-05-07 2018-09-04 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods of diagnosing or treating prostate cancer using the ERG gene, alone or in combination with other over or under expressed genes in prostate cancer
ATE551432T1 (de) 2004-06-21 2012-04-15 Univ Leland Stanford Junior Bei manisch-depressiver erkrankung und/oder schwerer depressiver erkrankung unterschiedlich exprimierte gene und wege
EP1769078A1 (fr) * 2004-07-01 2007-04-04 VIRxSYS Corporation Lignee cellulaire d'encapsidation de vecteurs
JP2008507540A (ja) 2004-07-21 2008-03-13 チューレン ユニバーシティ ヘルス サイエンス センター Ｐａｃａｐ化合物を用いる腎臓機能障害及び多発性骨髄腫の治療
CA2585717A1 (fr) 2004-10-27 2006-05-04 Medimmune Inc. Modulation d'une specificite d'anticorps par adaptation sur mesure de son affinite a un antigene apparente
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
WO2006069253A2 (fr) 2004-12-22 2006-06-29 Auckland Uniservices Limited Peptides en trefles et methodes de traitement des troubles proliferatifs au moyen desdits peptides
EP2520669A3 (fr) 2005-02-07 2013-02-27 GeneNews Inc. Biomarqueurs de l'ostéoarthrite douce et leurs utilisations
JP5153613B2 (ja) 2005-03-18 2013-02-27 メディミューン，エルエルシー 抗体のフレームワーク・シャッフル
EP1868650B1 (fr) 2005-04-15 2018-10-03 MacroGenics, Inc. Di-anticorps covalents et leurs utilisations
PT2573114T (pt) 2005-08-10 2016-07-13 Macrogenics Inc Identificação e manipulação de anticorpos com regiões fc variantes e métodos de utilização dos mesmos
CN102260742A (zh) 2005-10-21 2011-11-30 基因信息股份有限公司 用于使生物标志产物水平与疾病相关联的方法和装置
EP3299027A1 (fr) 2005-11-04 2018-03-28 Genentech, Inc. Utilisation d'inhibiteurs de la voie du complément pour traiter les maladies oculaires
CA2629299C (fr) 2005-11-12 2017-08-22 The Board Of Trustees Of The Leland Stanford Junior University Methodes associees au fgf2 pour diagnostiquer et traiter une depression
EP2387995A1 (fr) 2006-03-30 2011-11-23 PTC Therapeutics, Inc. Procédés pour la production d'une protéine fonctionnelle à partir d'ADN ayant une mutation non-sens et traitement de troubles associés
WO2008019199A2 (fr) 2006-06-26 2008-02-14 Macrogenics, Inc. ANTICORPS SPÉCIFIQUES DU FCγRIIB ET LEURS PROCÉDÉS D'UTILISATION
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
SG170032A1 (en) 2006-08-28 2011-04-29 Kyowa Hakko Kirin Co Ltd Antagonistic human light-specific human monoclonal antibodies
AU2007324128B2 (en) 2006-10-10 2013-10-10 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Prostate cancer-specific alterations in ERG gene expression and detection and treatment methods based on those alterations
AU2007313300A1 (en) 2006-10-16 2008-04-24 Medimmune, Llc. Molecules with reduced half-lives, compositions and uses thereof
AU2007323799B2 (en) 2006-11-15 2013-07-18 Eli Lilly And Company Anti-TSG101 antibodies and their uses for treatment of viral infections
TWI419904B (zh) 2006-12-18 2013-12-21 Genentech Inc 拮抗劑抗-ｎｏｔｃｈ３抗體及其用於預防及治療ｎｏｔｃｈ３相關疾病之用途
KR101799337B1 (ko) 2007-06-21 2017-12-20 마크로제닉스, 인크. 공유결합형 디아바디 및 이것의 사용
CN101932602B (zh) 2007-06-27 2017-05-24 新加坡国立大学 用于Artemin及相关配体的多肽和多核苷酸，及其使用方法
RU2015147300A (ru) 2007-08-29 2019-01-11 Санофи-Авентис Гуманизированные антитела к cxcr5, их производные и их применение
DK2247304T3 (en) 2008-04-02 2016-09-26 Macrogenics Inc Her2 / neu-specific antibodies and methods of use thereof
EP3045475B1 (fr) 2008-04-02 2017-10-04 MacroGenics, Inc. Anticorps specifiques du complexe bcr et procedes pour les utiliser
US7928189B2 (en) 2008-05-05 2011-04-19 Ottawa Health Research Institute PCSK9 polypeptide fragment
ES2675730T3 (es) 2008-06-04 2018-07-12 Macrogenics, Inc. Anticuerpos con unión alterada a FcRn y métodos de uso de los mismos
US8163497B2 (en) 2008-09-07 2012-04-24 Glyconex Inc. Anti-extended type I glycosphingolipid antibody, derivatives thereof and use
JP5734201B2 (ja) 2008-12-19 2015-06-17 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディ及びその使用
EP2367564A1 (fr) 2008-12-22 2011-09-28 Universität Regensburg Utilisation de la protéine norrin dans le traitement de maladies associées à une augmentation de l'activité de tgf-bêta
WO2010124365A1 (fr) 2009-04-27 2010-11-04 Ottawa Hospital Research Institute Compositions et méthodes permettant de moduler les cellules souches et leurs utilisations
ES2548030T3 (es) 2009-06-01 2015-10-13 Medimmune, Llc Moléculas con semividas prolongadas y usos de las mismas
DK2464664T3 (da) 2009-08-13 2016-01-18 Crucell Holland Bv Antistoffer mod humant respiratorisk syncytialvirus (rsv) og fremgangsmåder til anvendelse deraf
US20110189183A1 (en) 2009-09-18 2011-08-04 Robert Anthony Williamson Antibodies against candida, collections thereof and methods of use
WO2011046457A1 (fr) 2009-10-16 2011-04-21 Auckland Uniservices Limited Utilisations antinéoplasiques d'antagonistes d'artémine
CN102883739B (zh) 2009-11-02 2015-11-25 图兰恩教育基金管理人 垂体腺苷酸环化酶激活多肽（pacap）的类似物和它们的应用方法
EP2496604B1 (fr) 2009-11-06 2017-08-23 IDEXX Laboratories, Inc. Anticorps contre cd20 canine
CA2790245C (fr) 2010-02-19 2018-10-09 Universite De Liege Polynucleotide pour utilisation dans le traitement de maladies induites par l'influenzavirus a, codant pour une proteine mx modifiee, ladite proteine mx modifiee, et animal transgenique exprimant un gene codant pour une proteine mx modifiee
JP5744196B2 (ja) 2010-07-09 2015-07-08 クルセル ホランド ベー ヴェー 抗ヒト呼吸器多核体ウイルス（ｒｓｖ）抗体および使用の方法
WO2012013249A1 (fr) 2010-07-30 2012-02-02 Université de Liège Protéine 1 de la matrice dentinaire (dmp1) pour l'utilisation dans des compositions pharmaceutiques
CA2807127C (fr) 2010-08-02 2019-02-12 Leslie S. Johnson Di-anticorps covalents et utilisations associees
WO2012094511A2 (fr) 2011-01-05 2012-07-12 Rhode Island Hospital Compositions et procédés destinés au traitement de lésion ou de maladie orthopédique
KR102030531B1 (ko) 2011-05-21 2019-10-10 마크로제닉스, 인크. 탈면역화된 혈청-결합 도메인 및 혈청 반감기를 연장하기 위한 그것의 용도
KR20140062139A (ko) 2011-09-16 2014-05-22 페이트 세러퓨틱스, 인코포레이티드 Ｗnt 조성물 및 당해 조성물의 치료학적 용도
ES2690305T3 (es) 2011-09-16 2018-11-20 Ottawa Hospital Research Institute Composiciones de Wnt7a y métodos de utilización de las mismas
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
DK2814842T3 (en) 2012-02-15 2018-12-10 Novo Nordisk As ANTIBODIES BINDING PEPTIDOGLYCAN RECOGNITION PROTEIN 1
WO2013120553A1 (fr) 2012-02-15 2013-08-22 Novo Nordisk A/S Anticorps qui se lient et bloquent la stimulation d'un récepteur exprimé sur des cellules myéloïdes 1 (trem-1)
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
CA2877441A1 (fr) 2012-07-02 2014-01-09 Medizinische Universitat Wien Produit de separation du complement c4d pour le traitement d'affections inflammatoires
US20140120116A1 (en) 2012-10-26 2014-05-01 The Chinese University Of Hong Kong Treatment of cancer using smad3 inhibitor
WO2014120975A1 (fr) 2013-02-01 2014-08-07 California Institute Of Technology Immunocontraception à médiation par un anticorps
US10272117B2 (en) 2014-02-24 2019-04-30 Celgene Corporation Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
CN106413750B (zh) 2014-05-16 2022-04-29 免疫医疗有限责任公司 具有增强的治疗和诊断特性的带有改变的新生儿Fc受体结合的分子
US9458464B2 (en) 2014-06-23 2016-10-04 The Johns Hopkins University Treatment of neuropathic pain
EP3172232B1 (fr) 2014-07-17 2023-12-27 Novo Nordisk A/S Mutagenèse dirigée sur site d'anticorps trem-1 pour réduire la viscosité.
RU2756247C2 (ru) 2014-11-17 2021-09-28 Эдисет Био, Инк. Генетически модифицированные гамма дельта т-клетки
US10729790B2 (en) 2015-05-26 2020-08-04 Salk Institute For Biological Studies Motor neuron-specific expression vectors
US9920100B2 (en) 2015-06-05 2018-03-20 The Chinese University Of Hong Kong Mimotopes of tropomyosin for use in immunotherapy for shellfish and/or arthropod allergy
WO2017182981A1 (fr) 2016-04-20 2017-10-26 Washington University Agoniste de ppar ou agoniste de lxr à utiliser pour traiter le lupus érythémateux systémique par modulation de l'activité lap
AU2017261804A1 (en) 2016-05-12 2018-11-29 Adicet Therapeutics, Inc. Methods for selective expansion of γδ T-cell populations and compositions thereof
AU2018370120B2 (en) 2017-11-15 2023-11-09 Adicet Therapeutics, Inc. Methods for selective expansion of d3 yd T-cell populations and compositions thereof
DE102017127984B4 (de) 2017-11-27 2019-12-05 Immatics US, Inc. Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
PE20201343A1 (es) 2018-04-02 2020-11-25 Bristol Myers Squibb Co Anticuerpos anti-trem-1 y usos de los mismos
WO2020097261A1 (fr) 2018-11-06 2020-05-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nouvelles compositions et nouveaux procédés de traitement de globinopathies
WO2020117862A1 (fr) 2018-12-03 2020-06-11 Adicet Bio, Inc. Méthodes d'expansion sélective in vivo de populations de lymphocytes t gamma delta et compositions associées
WO2020243134A1 (fr) 2019-05-27 2020-12-03 Immatics US, Inc. Vecteurs viraux et leur utilisation dans une thérapie cellulaire adoptive
JP2023510195A (ja) 2020-01-03 2023-03-13 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 歯周の健康を促進するために局所投与されるｔｎａｐ
AU2021225817A1 (en) 2020-02-24 2022-10-20 Immatics US, Inc. Methods for expanding T cells for the treatment of cancer and related malignancies
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102021100038A1 (de) 2020-12-31 2022-06-30 Immatics US, Inc. Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung
CR20230295A (es) 2020-12-31 2023-07-27 Immatics Us Inc Polipéptidos cd8, composiciones y métodos de uso de estos
CA3206148A1 (fr) 2021-01-24 2022-07-28 Michael David FORREST Modificateurs therapeutiques du mode inverse de l'atp-synthase
IL308337A (en) 2021-05-13 2024-01-01 Us Health Preparations and methods for the treatment of sickle cell disease
AU2022314055A1 (en) 2021-07-19 2024-02-08 New York University Adeno-associated viral vector compositions and methods of promoting muscle regeneration
WO2023064255A2 (fr) 2021-10-15 2023-04-20 The Regents Of The University Of California Diagnostic et traitement de la thrombocytopénie induite par anti-pf4
WO2023081167A2 (fr) 2021-11-02 2023-05-11 The Regents Of The University Of California Mutants de p-sélectine et modulation de signalisation médiée par intégrine
WO2023131901A1 (fr) 2022-01-07 2023-07-13 Johnson & Johnson Enterprise Innovation Inc. Matériaux et procédés de protéines de liaison à il-1beta
WO2023146807A1 (fr) 2022-01-25 2023-08-03 The Regents Of The University Of California Mutants de vegf et modulation de signalisation médiée par intégrine
WO2023200897A1 (fr) 2022-04-13 2023-10-19 The Regents Of The University Of California Utilisation d'il-6 virale dans le traitement du cancer
US20230348548A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2023212691A1 (fr) 2022-04-28 2023-11-02 Immatics US, Inc. Polypeptides récepteurs de tgfβ négatifs dominants, polypeptides cd8, cellules, compositions et leurs méthodes d'utilisation
WO2023212655A1 (fr) 2022-04-28 2023-11-02 Immatics US, Inc. Polypeptides d'il-12, polypeptides d'il-15, polypeptides d'il-18, polypeptides de cd8, compositions et leurs procédés d'utilisation
WO2023215825A1 (fr) 2022-05-05 2023-11-09 Immatics US, Inc. Procédés d'amélioration de l'efficacité d'un lymphocyte t
WO2024013727A1 (fr) 2022-07-15 2024-01-18 Janssen Biotech, Inc. Matériau et procédés d'appariement amélioré par génie biologique de régions variables de liaison à l'antigène

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990012087A1 (fr) * 1989-04-05 1990-10-18 Novacell Corporation Particule virale infectieuse ciblee a replication defectueuse
WO1991002805A2 (fr) * 1989-08-18 1991-03-07 Viagene, Inc. Retrovirus de recombinaison apportant des constructions de vecteur a des cellules cibles
WO1992005266A2 (fr) * 1990-09-21 1992-04-02 Viagene, Inc. Cellules d'encapsidation
WO1992014829A1 (fr) * 1991-02-19 1992-09-03 The Regents Of The University Of California Particules virales agissant sur une gamme d'hotes modifiee
WO1993000103A1 (fr) * 1991-06-21 1993-01-07 The Wistar Institute Of Anatomy And Biology Proteines d'enveloppe chimeriques pour le ciblage de virus
WO1993005147A1 (fr) * 1991-08-30 1993-03-18 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Particules defectives interferentes du vih avec un cd-env chimerique
WO1993014188A1 (fr) * 1992-01-17 1993-07-22 The Regents Of The University Of Michigan Virus cible

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990012087A1 (fr) * 1989-04-05 1990-10-18 Novacell Corporation Particule virale infectieuse ciblee a replication defectueuse
WO1991002805A2 (fr) * 1989-08-18 1991-03-07 Viagene, Inc. Retrovirus de recombinaison apportant des constructions de vecteur a des cellules cibles
WO1992005266A2 (fr) * 1990-09-21 1992-04-02 Viagene, Inc. Cellules d'encapsidation
WO1992014829A1 (fr) * 1991-02-19 1992-09-03 The Regents Of The University Of California Particules virales agissant sur une gamme d'hotes modifiee
WO1993000103A1 (fr) * 1991-06-21 1993-01-07 The Wistar Institute Of Anatomy And Biology Proteines d'enveloppe chimeriques pour le ciblage de virus
WO1993005147A1 (fr) * 1991-08-30 1993-03-18 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Particules defectives interferentes du vih avec un cd-env chimerique
WO1993014188A1 (fr) * 1992-01-17 1993-07-22 The Regents Of The University Of Michigan Virus cible

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
EMBO J., vol. 7, no. 9, September 1988, OXFORD UNIVERSITY PRESS,GB;, pages 2839-2847, XP002025309 A. MARTIN ET AL.: "Engineering a poliovirus type 2 antigenic site on a type 1 capsid results in a chimaeric virus which is neurivirulent for mice" *
JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 266, no. 22, 5 August 1991, pages 14143-14146, XP000612122 HIROSHI NEDA ET AL: "CHEMICAL MODIFICATION OF AN ECOTROPIC MURINE LEUKEMIA VIRUS RESULTS IN REDIRECTION OF ITS TARGET CELL SPECIFICITY" *
JOURNAL OF VIROLOGY, vol. 66, no. 12, 1 December 1992, pages 7374-7382, XP002011560 DONG J ET AL: "A CHIMERIC AVIAN RETROVIRUS CONTAINING THE INFLUENZA VIRUS HEMAGGLUTININ GENE HAS AN EXPANDED HOST RANGE" *
PROC. NATL.ACAD SCI., vol. 89, January 1992, NATL. ACAD SCI.,WASHINGTON,DC,US;, pages 207-211, XP002025310 S.D. LONDON ET AL.: "Infectious enveloped RNA virus antigenic chimeras" *
See also references of WO9320221A1 *
VIROLOGY, vol. 163, no. 3, March 1988, ACADEMIC PRESS, INC.,NEW YORK, US, pages 251-254, XP000613633 B. GOUD ET AL.: "Antibody-mediated binding of a murine ecotropic miloney retroviral vector to human cells allows internalization but not the establishment of the proviral state" *

Also Published As

Publication number Publication date
JPH07505773A (ja) 1995-06-29
AU3940293A (en) 1993-11-08
WO1993020221A1 (fr) 1993-10-14
EP0633943A4 (fr) 1997-05-02
CA2133411A1 (fr) 1993-10-14

Similar Documents

Publication Publication Date Title
EP0633943A1 (fr) Therapie genique utilisant des vecteurs viraux cibles
Salmons et al. Targeting of retroviral vectors for gene therapy
ES2297831T3 (es) Vectores retroviricos que presentan una tasa de recombinacion reducida.
Tolstoshey Gene therapy, concepts, current trials and future directions
EP2344648B1 (fr) Vecteurs recombinants
DE69534792T2 (de) Verabreichung von komplettem faktor viii mit hilfe eines retroviralen systems
Frecha et al. Strategies for targeting lentiviral vectors
US20220169701A1 (en) Enveloped Virus Resistant to Complement Inactivation for the Treatment of Cancer
WO1993014188A1 (fr) Virus cible
WO1995030763A9 (fr) Vecteurs retroviraux a taux de recombinaison reduit
JPH10500852A (ja) 遺伝子治療のための安全なベクター
JPH09509329A (ja) 遺伝子搬送媒体を標的とする組成物及び方法
JP4011604B2 (ja) 後天性疾患治療用の新規移植組織片および新規ベクター
JP2002522090A (ja) 抗体エンベロープ融合タンパク質および野生型エンベロープタンパク質を含有するレトロウイルスベクターを用いる細胞型特異的遺伝子移入
US6448390B1 (en) Stable envelope proteins for retroviral, viral and liposome vectors and use in gene drug therapy
JP2001501441A (ja) 複製能力ウイルスの産生を阻害するための方法および組成物
JP3908274B2 (ja) 遺伝子治療用の抗菌ペプチドをコードする治療用遺伝子を有するベクター
US5736360A (en) Endothelial cell tropic compositions and methods of making and using the same
WO1999026480A1 (fr) Vecteurs de therapie genique anti-angiogenique et leurs applications dans le cadre du traitement d'affections liees a l'angiogenese
AU2001234025B2 (en) Mutated cyclin g1 protein
US20020035079A1 (en) Mutated cyclin G1 protein
Dickler et al. Gene therapy in the treatment of disease
JPH10512276A (ja) 遺伝子治療による治療薬の送達
AU780164B2 (en) Novel implant and novel vector for the treatment of acquired diseases
DE69829174T2 (de) Exprimierung eines modifiziertem "foamy virus envelope protein" (hüllenprotein)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19941020

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19970311

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19990618

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020709